bremelanotide
Peptide Target: MC4R, melanocortin receptor, GLP-1, PDE5
- Obesity
- Erectile Dysfunction
Palatin Technologies
Most recent annual filing: 2025-09-23
- Palatin corporate updateSep 2026Palatin corporate update, Sep 2026, routine
- Bivamelagon Rhythm Ph3 startby year-end 2026Bivamelagon Rhythm Ph3 start, by year-end 2026, routine
- Series J Warrants corporate updateMay 12, 2027Series J Warrants corporate update, May 12, 2027, notable
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (8 active programs)
PL9643
PL8177
PL7737
Small Molecule Target: MC4R
- Obesity
- Hypothalamic Obesity
- Undisclosed indication
- Prader-Willi Syndrome
Biotech Distilled coverage (1)
- 2026-09-07 Palatin Technologies (PTN) — Scientific Deep Dive for the MC4R Selective Agonist Programs and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.